

Please type a plus sign inside this box +

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/663,109
		Filing Date	September 15, 2003
		First Named Inventor	Rustum, et al.
		Art Unit	1614
		Examiner Name	Frederick F. Krass
Sheet	1	2	Attorney Docket Number

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/663,109
				Filing Date	September 15, 2003
				First Named Inventor	Rustum, et al.
				Group Art Unit	1614
				Examiner Name	Frederick F. Krass
Sheet	2	of	2	Attorney Docket Number	003551.00136

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	8	KONOREV, et. al., <i>Cell-Permeable Superoxide Dismutase and Glutathione Peroxidase Mimetics Afford Superior Protection Against Doxorubucin-Induced Cardiotoxicity: The Role of Reactive Oxygen and Nitrogen Intermediates</i> , Archives Biochem. Biophysics, 1999, 368 (2), pp. 421-428, abstract.			
	9	KORAC, et al., <i>Doxorubicin, Toxicity to the Skin: Possibility of Protection With Antioxidants Enriched Yeast</i> , J. Dermat. Sci., 2001, 25 (1) pp. 45-52, abstract.			
	10	CHEN, et al., <i>Protective Effects of Selenium Supplementation in Minimizing 5-Fluorouracil Induced Lipid Peroxidative Damage of the Small Intestine</i> , J. Trace Elements in Experimental Med., 1997, 10 (3), p. 163-171.			
	11	VADGAMA J. et. al., <i>Effect of Selenium in Combination With Adriamycin or Taxol on Several Different Cancer Cells</i> , Anticancer Research 20:1391-1414, 2000.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

BFLODOCS 2000765 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./